ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,213.49
0.51%
Dow Jones
38,675.68
1.18%
Gold vs US Dollar
2,302.57
0.00%
Brent Oil
82.765
0.00%
Bitcoin
63,669.71
1.24%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Apollomics Inc (APLMW)

  7. Apollomics Inc (APLMW) News

Apollomics (APLMW)

Apollomics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:APLMW
DateTimeSourceHeadlineSymbolCompany
25/04/202413:30GlobeNewswire Inc.Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion GeneNASDAQ:APLMWApollomics Inc
10/04/202412:00GlobeNewswire Inc.Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual MeetingNASDAQ:APLMWApollomics Inc
02/04/202413:00GlobeNewswire Inc.Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual MeetingNASDAQ:APLMWApollomics Inc
28/03/202411:00GlobeNewswire Inc.Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial ResultsNASDAQ:APLMWApollomics Inc
26/03/202412:00GlobeNewswire Inc.Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024NASDAQ:APLMWApollomics Inc
04/03/202412:00GlobeNewswire Inc.Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial OfficerNASDAQ:APLMWApollomics Inc
07/02/202412:00GlobeNewswire Inc.Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:APLMWApollomics Inc
19/01/202421:15GlobeNewswire Inc.Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyNASDAQ:APLMWApollomics Inc
17/01/202421:30GlobeNewswire Inc.Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology ConferenceNASDAQ:APLMWApollomics Inc
03/01/202412:00GlobeNewswire Inc.Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid LeukemiaNASDAQ:APLMWApollomics Inc
02/01/202421:30GlobeNewswire Inc.Apollomics to Present at the 2024 Biotech ShowcaseNASDAQ:APLMWApollomics Inc
04/12/202312:00GlobeNewswire Inc.Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping MutationNASDAQ:APLMWApollomics Inc
29/11/202312:30GlobeNewswire Inc.Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual ConferenceNASDAQ:APLMWApollomics Inc
28/11/202312:00GlobeNewswire Inc.Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)NASDAQ:APLMWApollomics Inc
16/11/202313:30GlobeNewswire Inc.Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung CancerNASDAQ:APLMWApollomics Inc
31/10/202312:30GlobeNewswire Inc.Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET DysregulationNASDAQ:APLMWApollomics Inc
26/10/202313:50GlobeNewswire Inc.Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET FusionNASDAQ:APLMWApollomics Inc
23/10/202313:30GlobeNewswire Inc.Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%NASDAQ:APLMWApollomics Inc
16/10/202323:55GlobeNewswire Inc.Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023NASDAQ:APLMWApollomics Inc
28/09/202321:17GlobeNewswire Inc.Apollomics Reports First Half 2023 Financial Results and Provides Corporate UpdateNASDAQ:APLMWApollomics Inc
06/09/202312:00GlobeNewswire Inc.Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:APLMWApollomics Inc
11/04/202313:30GlobeNewswire Inc.Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R. Bryan Miller SymposiumNASDAQ:APLMWApollomics Inc
30/03/202313:00GlobeNewswire Inc.Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on NasdaqNASDAQ:APLMWApollomics Inc
 Showing the most relevant articles for your search:NASDAQ:APLMW

Your Recent History

LSE
SCLP
Scancell
LSE
AGL
Angle
LSE
SCE
Surface Transforms
LSE
EEE
Empire Metals
LSE
FUM
Futura Medical
LSE
SRSP
Sirius Petroleum
LSE
MIN
Minoan
LSE
GFM
Griffin Mining
LSE
AAU
Ariana Resources
LSE
TERN
Tern
LSE
ENET
Ethernity Networks
LSE
GKP
Gulf Keystone Petroleum
LSE
JAY
Bluejay Mining
LSE
TRIN
Trinity Exploration & Pr...
LSE
YU.
Yu
LSE
BARC
Barclays
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved